faculty

Publications

Exploring predictive factors for adverse effects and treatment completion in Isoniazid preventive therapy among PLHIV on HAART: A single centre retrospective cohort study from South India

Groups and Associations henmozhi Nagarajan; Priyanka P; Abdul Mateen Athar; Uma Devi; GD Ravindran; Jyothi Idiculla
Panacea Journal of Medical Sciences 2025

Abstract Background: Factors associated with development of adverse effects and completion of IPT in India need to be explored, as this will help in better monitoring and completion rates. This study aimed to study the factors predicting the adverse effects and the completion of IPT. Materials and Methods: A retrospective cohort study was conducted on 802 patients initiated on IPT among People living with HIV (PLHIV) on Highly Active Anti-Retroviral Therapy (HAART). Data was collected from the routinely collected information, IPT records of the patients attending the ART center. All patients who were initiated on IPT were included irrespective of their completion status. Chi Square test and t test were conducted to study the associated factors of developing adverse effects and completion of IPT. Results: Among the 802 patients studied, mean age was 42.3 ± 9.3 years, with 55.9% (448/802) being male. The IPT completion rate was 96.3%. Adverse effects were observed in 4.36 % (n =35) and 3.7% (n=30) did not complete IPT. There was a significant association with non-completion of IPT and development of the adverse effects like Gastritis and peripheral neuropathy. Within the subset who developed adverse effects (n=35), 2.11 % successfully completed IPT and 2.24% did not. We found no association with age, gender, BMI, level of education, duration of HIV, CD4 counts, HbSAg status, and smoking, ethanol consumption with development of adverse effects or completion of IPT. Conclusion: IPT completion was (96.3 %) among the cohort studied. Symptoms Gastritis and peripheral neuropathy were significantly associated with noncompletion of IPT. We found no association with the duration of HAART, HIV, CD4 counts, age, gender with development of adverse effects and non